Loading...
Improved responses and survival have been realized in myeloma via combinations of immunomodulatory agents, proteasome inhibitors, and plasma-cell–targeting monoclonal antibodies. However, patients who develop treatment resistance have had limited therapeutic options. Investigators now report the results of a multicenter, industry-sponsored, open-label phase 1–2 trial of the novel oral cereblon modulator mezigdomide in combination with dexamethasone in patients with relapsed and refractory multiple myeloma.
The dose- and schedule-finding phase 1 cohort comprised 77 patients and the dose-expansion phase 2 cohort comprised 101 patients. Eligible patients had received three or more prior lines of therapy, including lenalidomide, pomalidomide, a …